

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61M 15/00, B65D 83/14, B05D 5/08		A1	(11) International Publication Number: WO 96/32151 (43) International Publication Date: 17 October 1996 (17.10.96)
<p>(21) International Application Number: PCT/US96/05006</p> <p>(22) International Filing Date: 10 April 1996 (10.04.96)</p> <p>(30) Priority Data: 08/422,111 14 April 1995 (14.04.95) US 08/584,859 5 January 1996 (05.01.96) US</p> <p>(60) Parent Applications or Grants (63) Related by Continuation US 08/422,111 (CIP) Filed on 14 April 1995 (14.04.95) US 08/584,859 (CIP) Filed on 5 January 1996 (05.01.96)</p> <p>(71) Applicant (<i>for all designated States except US</i>): GLAXO WELLCOME INC. [US/US]; 5 Moore Drive, Research Triangle Park, NC 27709 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): ASHURST, Ian, C. [GB/GB]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). HERMAN, Craig, S. [US/US]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). LI, Li [CH/US]; Glaxo</p>		<p>Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US). RIEBE, Michael, T. [US/US]; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US).</p> <p>(74) Agents: LEVY, David, J. et al.; Glaxo Wellcome Holdings plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	

(54) Title: **METERED DOSE INHALER FOR FLUTICASONE PROPIONATE**

(57) Abstract

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more nonfluorocarbon polymers, for dispensing an inhalation drug formulation comprising fluticasone propionate, or a physiologically acceptable solvate thereof, and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

METERED DOSE INHALER FOR FLUTICASONE PROPIONATE

BACKGROUND OF THE INVENTION

5

Drugs for treating respiratory and nasal disorders are frequently administered in aerosol formulations through the mouth or nose. One widely used method for dispensing such aerosol drug formulations involves making a suspension formulation of the drug as a finely divided powder in a liquefied gas known as a propellant. The suspension is stored in a sealed container capable of 10 withstanding the pressure required to maintain the propellant as a liquid. The suspension is dispersed by activation of a dose metering valve affixed to the container.

15

A metering valve may be designed to consistently release a fixed, predetermined mass of the drug formulation upon each activation. As the suspension is forced from the container through the dose metering valve by the high vapor pressure of the propellant, the propellant rapidly vaporizes leaving a fast moving cloud of very fine particles of the drug formulation. This cloud of particles is directed into the 20 nose or mouth of the patient by a channelling device such as a cylinder or open-ended cone. Concurrently with the activation of the aerosol dose metering valve, the patient inhales the drug particles into the lungs or nasal cavity. Systems of dispensing drugs in this way are known as "metered dose inhalers"(MDI's). See Peter Byron, Respiratory Drug Delivery, CRC Press, Boca Raton, FL (1990) for a 25 general background on this form of therapy.

25

Patients often rely on medication delivered by MDI's for rapid treatment of respiratory disorders which are debilitating and in some cases, even life threatening. Therefore, it is essential that the prescribed dose of aerosol 30 medication delivered to the patient consistently meet the specifications claimed by the manufacturer and comply with the requirements of the FDA and other regulatory authorities. That is, every dose in the can must be the same within close tolerances.

Some aerosol drugs tend to adhere to the inner surfaces, i.e., walls of the can, valves, and caps, of the MDI. This can lead to the patient getting significantly less than the prescribed amount of drug upon each activation of the MDI. The problem is particularly acute with hydrofluoroalkane (also known as simply "fluorocarbon") propellant systems, e.g., P134a and P227, under development in recent years to replace chlorofluorocarbons such as P11, P114 and P12.

We have found that coating the interior can surfaces of MDI's with a fluorocarbon polymer significantly reduces or essentially eliminates the problem of adhesion or deposition of fluticasone propionate on the can walls and thus ensures consistent delivery of medication in aerosol from the MDI.

SUMMARY OF THE INVENTION

A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising fluticasone propionate, or a physiologically acceptable solvate thereof, and a fluorocarbon propellant optionally in combination with one or more other pharmacologically active agents or one or more excipients.

DETAILED DESCRIPTION OF THE INVENTION

The term "metered dose inhaler" or "MDI" means a unit comprising a can, a crimped cap covering the mouth of the can, and a drug metering valve situated in the cap, while the term "MDI system" also includes a suitable channelling device. The terms "MDI can" means the container without the cap and valve. The term "drug metering valve" or "MDI valve" refers to a valve and its associated mechanisms which delivers a predetermined amount of drug formulation from an MDI upon each activation. The channelling device may comprise, for example, an actuating device for the valve and a cylindrical or cone-like passage through which medicament may be delivered from the filled MDI can via the MDI valve to the nose or mouth of a patient, e.g. a mouthpiece actuator. The relation of the

parts of a typical MDI is illustrated in US Patent 5,261,538 incorporated herein by reference.

The term "fluorocarbon polymers" means a polymer in which one or more of the
5 hydrogen atoms of the hydrocarbon chain have been replaced by fluorine atoms.
Thus, "fluorocarbon polymers" include perfluorocarbon, hydrofluorocarbon,
chlorofluorocarbon, hydro-chlorofluorocarbon polymers or other halogen
substituted derivatives thereof. The "fluorocarbon polymers" may be branched,
homo-polymers or co-polymers.

10 U.S. Patent No. 4,335,121, incorporated herein by reference, teaches an
antiinflammatory steroid compound known by the chemical name [(6a, 11b, 16a,
17a)-6, 9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy) androsta-1, 4-
diene-17-carbothioic acid, S-fluoromethyl ester and the generic name "fluticasone
15 propionate". Fluticasone propionate in aerosol form, has been accepted by the
medical community as useful in the treatment of asthma and is marketed under
the trademarks "Flovent" and "Flonase". Fluticasone propionate may also be
used in the form of a physiologically acceptable solvate.

20 The term "drug formulation" means fluticasone propionate (or a physiologically
acceptable solvate thereof) optionally in combination with one or more other
pharmacologically active agents such as other antiinflammatory agents,
analgesic agents or other respiratory drugs and optionally containing one or more
excipients, and a fluorocarbon propellant. The term "excipients" as used herein
25 means chemical agents having little or no pharmacological activity (for the
quantities used) but which enhance the drug formulation or the performance of
the MDI system. For example, excipients include but are not limited to
surfactants, preservatives, flavorings, antioxidants, antiaggregating agents, and
cosolvents, e.g., ethanol and diethyl ether.

30 Suitable surfactants are generally known in the art, for example, those
surfactants disclosed in European Patent Application No. 0327777. The amount
of surfactant employed is desirably in the range of 0.0001% to 50% weight to
weight ratio relative to the drug, in particular 0.05 to 5% weight to weight ratio. A

particularly useful surfactant is 1,2-di[7-(F-hexyl) hexanoyl]-glycero-3-phospho-N,N,N-trimethylethanolamine also known as 3, 5, 9-trioxa-4-phosphadocosan-1-aminium, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 22-tridecafluoro-7-[(8, 8, 9, 9, 10, 10, 11, 11, 12, 12, 13, 13, 13-tridecafluoro-1-oxotridecyl)oxy]-4-hydroxy-N, N,N-trimethyl-10-oxo-, inner salt, 4-oxide.

A polar cosolvent such as C₂₋₆ aliphatic alcohols and polyols e.g. ethanol, isopropanol and propylene glycol, preferably ethanol, may be included in the drug formulation in the desired amount, either as the only excipient or in addition to other excipients such as surfactants. Suitably, the drug formulation may contain 0.01 to 5% w/w based on the propellant of a polar cosolvent e.g. ethanol, preferably 0.1 to 5% w/w e.g. about 0.1 to 1% w/w.

It will be appreciated by those skilled in the art that the drug formulation for use in the invention may, if desired, contain fluticasone propionate (or a physiologically acceptable solvate thereof) in combination with one or more other pharmacologically active agents. Such medicaments may be selected from any suitable drug useful in inhalation therapy. Appropriate medicaments may thus be selected from, for example, analgesics, e.g. codeine, dihydromorphine, ergotamine, fentanyl or morphine; anginal preparations, e.g. diltiazem; antiallergics, e.g. cromoglycate, ketotifen or nedocromil; antiinfectives e.g. cephalosporins, penicillins, streptomycin, sulphonamides, tetracyclines and pentamidine; antihistamines, e.g. methapyrilene; anti-inflammatories, e.g. beclomethasone (e.g. the dipropionate), flunisolide, budesonide, tipredane or triamcinolone acetonide; antitussives, e.g. noscapine; bronchodilators, e.g. salbutamol, salmeterol, ephedrine, adrenaline, fenoterol, formoterol, isoprenaline, metaproterenol, phenylephrine, phenylpropanolamine, pirbuterol, reproterol, rimiterol, terbutaline, isoetharine, tulobuterol, orciprenaline, or (-)-4-amino-3,5-dichloro- α -[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]methyl]benzenemethanol; diuretics, e.g. amiloride; anticholinergics e.g. ipratropium, atropine or oxitropium; hormones, e.g. cortisone, hydrocortisone or prednisolone; xanthines e.g. aminophylline, choline theophyllinate, lysine theophyllinate or theophylline; and therapeutic proteins and peptides, e.g. insulin or glucagon. It will be clear to a person skilled in the art that, where appropriate, the medicaments may be used in

the form of salts (e.g. as alkali metal or amine salts or as acid addition salts) or as esters (e.g. lower alkyl esters) or as solvates (e.g. hydrates) to optimise the activity and/or stability of the medicament and/or to minimise the solubility of the medicament in the propellant.

5

Particularly preferred drug formulations contain fluticasone propionate (or a physiologically acceptable solvate thereof) in combination with a bronchodilator such as salbutamol (e.g. as the free base or the sulphate salt) or salmeterol (e.g. as the xinafoate salt).

10

A particularly preferred drug combination is fluticasone propionate and salmeterol xinafoate.

15

"Propellants" used herein mean pharmacologically inert liquids with boiling points from about room temperature (25°C) to about -25°C which singly or in combination exert a high vapor pressure at room temperature. Upon activation of the MDI system, the high vapor pressure of the propellant in the MDI forces a metered amount of drug formulation out through the metering valve then the propellant very rapidly vaporizes dispersing the drug particles. The propellants used in the present invention are low boiling fluorocarbons; in particular, 1,1,1,2-tetrafluoroethane also known as "propellant 134a" or "P 134a" and 1,1,1,2,3,3-heptafluoro-n-propane also known as "propellant 227" or "P 227".

20

Drug formulations for use in the invention may be free or substantially free of formulation excipients e.g. surfactants and cosolvents etc. Such drug formulations are advantageous since they may be substantially taste and odour free, less irritant and less toxic than excipient-containing formulations. Thus, a preferred drug formulation consists essentially of fluticasone propionate, or a physiologically acceptable salt thereof, optionally in combination with one or more other pharmacologically active agents particularly salmeterol (e.g. in the form of the xinafoate salt), and a fluorocarbon propellant. Preferred propellants are 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3-heptafluoro-n-propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane.

Further drug formulations for use in the invention may be free or substantially free of surfactant. Thus, a further preferred drug formulation comprises or consists essentially of albuterol (or a physiologically acceptable salt thereof), optionally in combination with one or more other pharmacologically active agents, a
5 fluorocarbon propellant and 0.01 to 5% w/w based on the propellant of a polar cosolvent, which formulation is substantially free of surfactant. Preferred propellants are 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3-heptafluoro-n-propane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3-heptafluoro-n-propane.

10 Most often the MDI can and cap are made of aluminum or an alloy of aluminum, although other metals not affected by the drug formulation, such as stainless steel, an alloy of copper or tin plate, may be used. An MDI can may also be fabricated from glass or plastic. Preferably, however, the MDI cans employed in
15 the present invention are made of aluminium or an alloy thereof. Advantageously, strengthened aluminium or aluminum alloy MDI cans may be employed. Such strengthened MDI cans are capable of withstanding particularly stressful coating and curing conditions, e.g. particularly high temperatures, which may be required for certain fluorocarbon polymers. Strengthened MDI cans
20 which have a reduced tendency to malform under high temperatures include MDI cans comprising side walls and a base of increased thickness and MDI cans comprising a substantially ellipsoidal base (which increases the angle between the side walls and the base of the can), rather than the hemispherical base of standard MDI cans. MDI cans having an ellipsoidal base offer the further
25 advantage of facilitating the coating process.

The drug metering valve consists of parts usually made of stainless steel, a pharmacologically inert and propellant resistant polymer, such as acetal, polyamide (e.g., Nylon[®]), polycarbonate, polyester, fluorocarbon polymer (e.g.,
30 Teflon[®]) or a combination of these materials. Additionally, seals and "O" rings of various materials (e.g., nitrile rubbers, polyurethane, acetyl resin, fluorocarbon polymers), or other elastomeric materials are employed in and around the valve.

Fluorocarbon polymers for use in the invention include fluorocarbon polymers which are made of multiples of one or more of the following monomeric units: tetrafluoroethylene (PTFE), fluorinated ethylene propylene (FEP), perfluoroalkoxyalkane (PFA), ethylene tetrafluoroethylene (ETFE), vinyldienefluoride (PVDF), and chlorinated ethylene tetrafluoroethylene. 5 Fluorinated polymers which have a relatively high ratio of fluorine to carbon, such as perfluorocarbon polymers e.g. PTFE, PFA, and FEP, are preferred.

10 The fluorinated polymer may be blended with non-fluorinated polymers such as polyamides, polyimides, polyethersulfones, polyphenylene sulfides and amine-formaldehyde thermosetting resins. These added polymers improve adhesion of the polymer coating to the can walls. Preferred polymer blends are PTFE/FEP/polyamideimide, PTFE/polyethersulphone (PES) and FEP-benzoguanamine.

15 Particularly preferred coatings are pure PFA, FEP and blends of PTFE and polyethersulphone (PES).

20 Fluorocarbon polymers are marketed under trademarks such as Teflon®, Tefzel®, Halar®, Hostaflon® Polyflon® and Neoflon®. Grades of polymer include FEP DuPont 856-200, PFA DuPont 857-200, PTFE-PES DuPont 3200-100, PTFE-FEP-polyamideimide DuPont 856P23485, FEP powder DuPont 532, and PFA Hoechst 6900n. The coating thickness is in the range of about 1 µm to about 1 mm. Suitably the coating thickness is in the range of about 1 µm to about 100 µm, e.g. 1 µm to 25 µm. Coatings may be applied in one or more coats.

25 Preferably the fluorocarbon polymers for use in the invention are coated onto MDI cans made of metal, especially MDI cans made of aluminium or an alloy thereof.

30 The particle size of the particular (e.g., micronised) drug should be such as to permit inhalation of substantially all the drug into the lungs upon administration of the aerosol formulation and will thus be less than 100 microns, desirably less than 20 microns, and, in particular, in the range of 1-10 microns, e.g., 1-5 microns.

The final drug formulation desirably contains 0.005-10% weight to weight ratio, in particular 0.005-5% weight to weight ratio, especially 0.01-1.0% weight to weight ratio, of drug relative to the total weight of the formulation.

- 5 A further aspect of the present invention is a metered dose inhaler having part or all of its internal metallic surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispersing an inhalation drug formulation comprising fluticasone propionate
10 and a fluorocarbon propellant optionally in combination with one or more other pharmacologically active agents and one or more excipients.
- 15 A particular aspect of the present invention is an MDI having part or essentially all of its internal metallic surfaces coated with PFA or FEP, or blended fluoropolymer resin systems such as PTFE-PES with or without a primer coat of a polyamideimide or polyethersulfone for dispensing a drug formulation as defined hereinabove. Preferred drug formulations for use in this MDI consist essentially of fluticasone propionate (or a physiologically acceptable solvate, thereof), optionally in combination with one or more other pharmacologically active agents
20 particularly salmeterol (e.g. in the form of the xinafoate salt), and a fluorocarbon propellant, particularly 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane or mixtures thereof, and especially 1,1,1,2-tetrafluoroethane. Preferably the MDI can is made of aluminium or an alloy thereof.
- 25 The MDI can may be coated by the means known in the art of metal coating. For example, a metal, such as aluminum or stainless steel, may be precoated as coil stock and cured before being stamped or drawn into the can shape. This method is well suited to high volume production for two reasons. First, the art of coating coil stock is well developed and several manufacturers can custom coat metal
30 coil stock to high standards of uniformity and in a wide range of thicknesses. Second, the precoated stock can be stamped or drawn at high speeds and precision by essentially the same methods used to draw or stamp uncoated stock.

Other techniques for obtaining coated cans is by electrostatic dry powder coating or by spraying preformed MDI cans inside with formulations of the coating fluorinated polymer/polymer blend and then curing. The preformed MDI cans may also be dipped in the fluorocarbon polymer/polymer blend coating formulation and cured, thus becoming coated on the inside and out. The fluorocarbon polymer/polymer blend formulation may also be poured inside the MDI cans then drained out leaving the insides with the polymer coat. Conveniently, for ease of manufacture, preformed MDI cans are spray-coated with the fluorinated polymer/polymer blend.

The fluorocarbon polymer/polymer blend may also be formed in situ at the can walls using plasma polymerization of the fluorocarbon monomers. Fluorocarbon polymer film may be blown inside the MDI cans to form bags. A variety of fluorocarbon polymers such as ETFE, FEP, and PTFE are available as film stock.

The appropriate curing temperature is dependent on the fluorocarbon polymer/polymer blend chosen for the coating and the coating method employed. However, for coil coating and spray coating temperatures in excess of the melting point of the polymer are typically required, for example, about 50°C above the melting point, for up to about 20 minutes such as about 5 to 10 minutes e.g. about 8 minutes or as required. For the above named preferred and particularly preferred fluorocarbon polymer/polymer blends curing temperatures in the range of about 300°C to about 400°C, e.g. about 350°C to 380°C are suitable for plasma polymerization typically temperatures in the range of about 20°C to about 100°C may be employed.

The MDI's taught herein may be prepared by methods of the art (e.g., see Byron, above and U.S. patent 5,345,980) substituting conventional cans for those coated with a fluorinated polymer/polymer blend. That is, fluticasone propionate and other components of the formulation are filled into an aerosol can coated with a fluorinated polymer/polymer blend. The can is fitted with a cap assembly which is crimped in place. The suspension of the drug in the fluorocarbon propellant in liquid form may be introduced through the metering valve as taught in U.S. 5,345,980 incorporated herein by reference.

The MDI's with fluorocarbon polymer/polymer blend coated interiors taught herein may be used in medical practice in a similar manner as non-coated MDI's now in clinical use. However the MDI's taught herein are particularly useful for containing and dispensing inhaled drug formulations with hydrofluoroalkane/fluorocarbon propellants such as 134a with little, or essentially no, excipient and which tend to deposit or cling to the interior walls and parts of the MDI system. In certain cases it is advantageous to dispense an inhalation drug with essentially no excipient, e.g., where the patient may be allergic to an excipient or the drug reacts with an excipient.

MDI's containing the formulations described hereinabove, MDI systems and the use of such MDI systems for the treatment of respiratory disorders e.g. asthma comprise further aspects of the present invention.

It will be apparent to those skilled in the art that modifications to the invention described herein can readily be made without departing from the spirit of the invention. Protection is sought for all the subject matter described herein including any such modifications.

The following non-limitative Examples serve to illustrate the invention.

EXAMPLES

25

Example 1

Standard 12.5 ml MDI cans (Presspart Inc., Cary, NC) were spray-coated (Livingstone Coatings, Charlotte, NC) with primer (DuPont 851-204) and cured to the vendor's standard procedure, then further spray-coated with either FEP or PFA (DuPont 856-200 and 857-200, respectively) and cured according to the vendor's standard procedure. The thickness of the coating is approximately 10 µm to 50 µm. These cans are then purged of air (see PCT application number WO94/22722 (PCT/EP94/00921)), the valves crimped in place, and a suspension

of about 20 mg fluticasone propionate in about 12 gm P134a is filled through the valve.

Example 2

5

Standard 0.46 mm thick aluminum sheet (United Aluminum) was spray-coated (DuPont, Wilmington, DE) with FEP (DuPont 856-200) and cured. This sheet was then deep-drawn into cans (Presspart Inc., Cary, NC). The thickness of the coating is approximately 10 µm to 50 µm. These cans are then purged of air, the valves crimped in place, and a suspension of about 40 mg fluticasone propionate in about 12 gm P134A is filled through the valve.

10

Example 3

15

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 µm and approximately 20 µm. These cans are then purged of air, the valves crimped in place, and a suspension of about 41.0 mg, 21.0 mg, 8.8 mg or 4.4 mg micronised fluticasone propionate in about 12 g P134a is filled through the valve.

20

Example 4

25

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 µm and approximately 20 µm. These cans are then purged of air the valves crimped in place, and a suspension of about 41.0 mg, 21.0 mg, 8.8 mg or 4.4 mg micronised fluticasone propionate in about 12 g P134a is filled through the valve.

30

Example 5

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the

12

coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of about 41.0 mg, 21.0 mg, 8.8 mg or 4.4 mg micronised fluticasone propionate in about 12 g P134a was filled through the valve.

5

Example 6

Standard 0.46 mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These 10 cans are then purged of air, the valves crimped in place, and a suspension of about 41.0 mg, 21.0 mg, 8.8 mg, or 4.4 mg micronised fluticasone propionate in about 12 g P134a is filled through the valve.

15

Example 7

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These 20 cans are then purged of air, the valves crimped in place, and a suspension of about 41.0 mg, 21.0 mg, 8.8 mg, or 4.4 mg micronised fluticasone propionate in about 12 g P134a is filled through the valve.

Example 8

25 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of about 8.8 mg, 22 mg or 44 mg of micronised fluticasone propionate with about 6.4 mg micronised salmeterol xinafoate in 30 about 12 g P134a is filled through the valve.

Example 9

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air the valves crimped in place, and a suspension of about 8.8 mg, 22 mg or 44 mg of micronised fluticasone propionate with about 6.4 mg micronised salmeterol xinafoate in about 12 g P134a is filled through the valve.

10

Example 10

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of about 8.8 mg, 22 mg or 44 mg of micronised fluticasone propionate with about 6.4 mg micronised salmeterol xinafoate in about 12 g P134a is filled through the valve.

20

Example 11

Standard 0.46 mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and a suspension of about 8.8 mg, 22 mg or 44 mg of micronised fluticasone propionate with about 6.4 mg micronised salmeterol xinafoate in about 12 g P134a is filled through the valve.

Example 12

30

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of

14

about 8.8 mg, 22 mg or 44 mg of micronised fluticasone propionate with about 6.4 mg micronised salmeterol xinafoate in about 12 g P134a is filled through the valve.

5

Example 13

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-PES blend (DuPont) as a single coat and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μm 10 and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of about 5.5 mg, 13.8 mg or 27.5 mg micronised fluticasone propionate with about 4 mg micronised salmeterol xinafoate in about 8 g P134a is filled through the valve.

15

Example 14

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with PTFE-FEP-polyamideimide blend (DuPont) and cured according to the vendor's standard procedure. The thickness of the coating is between approximately 1 μm 20 and approximately 20 μm . These cans are then purged of air the valves crimped in place, and a suspension of about 5.5 mg, 13.8 mg or 27.5 mg micronised fluticasone propionate with about 4 mg micronised salmeterol xinafoate in about 8 g P134a is filled through the valve.

25

Example 15

Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with FEP powder (DuPont FEP 532) using an electrostatic gun. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans 30 are then purged of air, the valves crimped in place, and a suspension of about 5.5 mg, 13.8 mg or 27.5 mg micronised fluticasone propionate with abou, 4 mg micronised salmeterol xinafoate in about 8 g P134a is filled through the valve.

Example 16

- 5 Standard 0.46 mm thick aluminium sheet is spray coated with FEP-Benzoguanamine and cured. This sheet is then deep-drawn into cans. These cans are then purged of air, the valves crimped in place, and a suspension of about 5.5 mg, 13.8 mg or 27.5 mg micronised fluticasone propionate with about 4 mg micronised salmeterol xinafoate in about 8 g P134a is filled through the valve.

Example 17

- 10 Standard 12.5 ml MDI cans (Presspart Inc., Cary NC) are spray-coated with an aqueous dispersion of PFA (Hoechst PFA-6900n) and cured. The thickness of the coating is between approximately 1 μm and approximately 20 μm . These cans are then purged of air, the valves crimped in place, and a suspension of 15 about 5.5 mg, 13.8 mg or 27.5 mg micronised fluticasone propionate with about 4 mg micronised salmeterol xinafoate in about 8 g P134a is filled through the valve.

Examples 18-22

- 20 Examples 3 to 7 are repeated except that a suspension of about 13.3 mg micronised fluticasone propionate in about 21.4 g P227 is filled through the valve.

Examples 23-27

- 25 Examples 3 to 7 are repeated except that 66 mg, or 6.6 mg micronised fluticasone propionate in about 182 mg ethanol and about 18.2 g P134a is filled through the valve.

Examples 28-52

- 30 Examples 3 to 27 are repeated except that modified 12.5 ml MDI cans having a substantially ellipsoidal base (Presspart Inc., Cary NC) were used.

Dose delivery from the MDIs tested under simulated use conditions is found to be constant, compared to control MDIs filled into uncoated cans which exhibit a significant decrease in dose delivered through use.

We claim:

1. A metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers, for dispensing an inhalation drug formulation comprising fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant, optionally in combination with one or more other pharmacologically active agents or one or more excipients.
5
2. An inhaler according to Claim 1 containing said drug formulation.
10
3. An inhaler according to Claim 2, wherein said drug formulation further comprises a surfactant.
15
4. An inhaler according to Claim 2 or Claim 3, wherein said drug formulation further comprises a polar cosolvent.
20
5. An inhaler according to Claim 2 wherein said drug formulation further comprises 0.01 to 5% w/w based upon propellant of a polar cosolvent, which formulation is substantially free of surfactant.
25
6. An inhaler according to any one of Claims 2 to 5, wherein said drug formulation comprises fluticasone propionate or a physiologically acceptable solvate thereof in combination with a bronchodilator or an antiallergic.
30
7. An inhaler according to Claim 6, wherein said drug formulation comprises fluticasone propionate in combination with salmeterol xinafoate.
8. An inhaler according to Claim 2, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof, optionally in combination with one or more other pharmacologically active agents, and a fluorocarbon propellant.

9. An inhaler according to Claim 8, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof in combination with a bronchodilator or an antiallergic.
- 5 10. An inhaler according to Claim 9, wherein said drug formulation consists essentially of fluticasone propionate or a physiologically acceptable solvate thereof in combination with salmeterol or a physiologically acceptable salt thereof.
- 10 11. An inhaler according to Claim 10, wherein said drug formulation consists essentially of fluticasone propionate in combination with salmeterol xinafoate.
- 15 12. An inhaler according to Claim 2, wherein said drug formulation consists of fluticasone propionate or a physiologically acceptable solvate thereof and a fluorocarbon propellant.
13. An inhaler according to any one of Claims 2 to 12, wherein the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane, or 1,1,1,2,3,3,3-heptafluoro-n-propane or mixtures thereof.
- 20 14. An inhaler according to Claim 13, wherein the fluorocarbon propellant is 1,1,1,2-tetrafluoroethane.
- 25 15. An inhaler according to any one of Claims 1 to 14 comprising a can made of metal wherein part or all of the internal metallic surfaces are coated.
16. An inhaler according to Claim 15 wherein the metal is aluminium or an alloy thereof.
- 30 17. An inhaler according to any one of Claims 1 to 16 wherein said fluorocarbon polymer is a perfluorocarbon polymer.
18. An inhaler according to Claim 17 wherein said fluorocarbon polymer is selected from PTFE, PFA, FEP and mixtures thereof.

19. An inhaler according to any one of Claims 1 to 18, wherein said fluorocarbon polymer is in combination with a non-fluorocarbon polymer selected from polyamideimide and polyethersulphone.

5

20. An inhaler according to any one of Claims 1 to 19 comprising a substantially ellipsoidal base.

10 21. A metered dose inhaler system comprising a metered dose inhaler according to any one of Claim 1 to 20 fitted into suitable channelling device for oral or nasal inhalation of the drug formulation.

22. Use of a metered dose inhaler system according to Claim 21 for the treatment of respiratory disorders.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/05006

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61M15/00 B65D83/14 B05D5/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61M B65D B05D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 642 992 (CIBA-GEIGY AG) 15 March 1995	1,17,18
Y	see column 4, line 50 - column 5, line 6; claims 5-8 ---	2-13,15, 16,19-22
Y	WO,A,93 11745 (GLAXO GROUP LTD.) 24 June 1993 see abstract see page 4, line 9 - page 5, line 9 ---	2,4-13, 15,16
Y	WO,A,92 08446 (GLAXO GROUP LTD.) 29 May 1992 see page 3, last paragraph - page 4, paragraph 1 ---	3
Y	EP,A,0 343 015 (SUMITOMO LTD.) 23 November 1989 see claims 1,10 ---	19
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search 22 July 1996	Date of mailing of the international search report 01.08.96
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentdienst 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016	Authorized officer Villeneuve, J-M

INTERNATIONAL SEARCH REPORT

Inte...inal Application No
PCT/US 96/05006

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP,A,0 465 741 (MITSUI TOATSU CHEMICALS ; TOKAI CORP (JP)) 15 January 1992 see claim 6 ---	20-22
A	US,A,5 176 132 (DROUGHT ET AL.) 5 January 1993 see column 3, paragraph 3 ---	1
A	WO,A,92 20391 (ABBOTT LABS) 26 November 1992 see abstract -----	20-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Appl. No	
PCT/US 96/05006	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-642992	15-03-95	AU-B-	7142994	09-03-95
		CA-A-	2130867	28-02-95
		JP-A-	7076380	20-03-95
-----	-----	-----	-----	-----
WO-A-9311745	24-06-93	AT-T-	128350	15-10-95
		AU-B-	663906	26-10-95
		AU-B-	3085292	19-07-93
		CA-A-	2125665	24-06-93
		DE-D-	69205177	02-11-95
		DE-T-	69205177	21-03-96
		EP-A-	0616525	28-09-94
		ES-T-	2079210	01-01-96
		JP-T-	7501811	23-02-95
		NZ-A-	246046	21-12-95
		ZA-A-	9209618	09-08-93
		AP-A-	402	22-08-95
		AU-B-	663904	26-10-95
		AU-B-	3085092	19-07-93
		AU-B-	663905	26-10-95
		AU-B-	3085192	19-07-93
		BG-A-	98803	28-02-95
		CA-A-	2125666	24-06-93
		CA-A-	2125667	24-06-93
		CN-A-	1075078	11-08-93
		CN-A-	1075079	11-08-93
		CZ-A-	9401430	15-03-95
		WO-A-	9311743	24-06-93
		WO-A-	9311744	24-06-93
		EP-A-	0616523	28-09-94
		EP-A-	0616524	28-09-94
		HU-A-	67534	28-04-95
		JP-T-	7502033	02-03-95
		JP-T-	7502034	02-03-95
		NO-A-	942185	10-06-94
		NZ-A-	246044	26-01-96
		OA-A-	9926	15-09-94
		SK-A-	67494	08-03-95
-----	-----	-----	-----	-----
WO-A-9208446	29-05-92	AT-T-	127013	15-09-95
		AU-B-	660952	13-07-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l. Appl. No.

PCT/US 96/05006

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9208446		AU-B-	8877891	11-06-92
		CA-A-	2094726	10-05-92
		DE-D-	69112637	05-10-95
		DE-T-	69112637	08-02-96
		EP-A-	0556256	25-08-93
		ES-T-	2078551	16-12-95
		JP-T-	6501700	24-02-94
EP-A-343015	23-11-89	JP-A-	2089633	29-03-90
		US-A-	5009959	23-04-91
EP-A-0465741	15-01-92	US-A-	5083685	28-01-92
		AU-B-	614234	22-08-91
		AU-A-	5798690	22-08-91
US-A-5176132	05-01-93	US-A-	5482946	09-01-96
		US-A-	5341800	30-08-94
		AT-T-	111364	15-09-94
		CA-A-	2017883	30-11-90
		DE-D-	69012458	20-10-94
		DE-T-	69012458	09-03-95
		DE-T-	407028	17-03-94
		EP-A-	0407028	09-01-91
		ES-T-	2060040	16-11-94
		JP-A-	3018376	25-01-91
WO-A-9220391	26-11-92	AU-B-	663093	28-09-95
		AU-B-	2006592	30-12-92
		CA-A-	2107792	22-11-92
		EP-A-	0585379	09-03-94
		HU-A-	67175	28-02-95
		JP-T-	6507801	08-09-94
		NO-A-	934186	20-01-94
		PT-A-	100504	31-05-94